Patient characteristics
Characteristic . | Training data set . | Validation data set . |
|---|---|---|
| Median age at transplantation, y (range) | 36.7 (0.7-55.1) | 35.8 (6.4-54.6) |
| No. younger than 18 y (%) | 13 (7) | 12 (6) |
| CML phase at time of transplantation, no. (%) | ||
| Chronic | 130 (67) | 142 (74) |
| Accelerated | 49 (25) | 38 (20) |
| Blast crisis | 12 (6) | 13 (7) |
| Juvenile | 2 (1) | 0 (0) |
| HLA allele match status, no. (%) | ||
| 10 of 10 matched | 91 (47) | 92 (48) |
| 9 of 10 matched | 46 (24) | 54 (28) |
| 8 or fewer of 10 matched | 56 (29) | 47 (24) |
| No. male patients (%) | 112 (58) | 110 (57) |
| GVHD prophylaxis, no. (%) | ||
| Calcineurin inhibitor + MTX* | 173 (90) | 168 (87) |
| Calcineurin inhibitor + MTX + other† | 20 (10) | 25 (13) |
Characteristic . | Training data set . | Validation data set . |
|---|---|---|
| Median age at transplantation, y (range) | 36.7 (0.7-55.1) | 35.8 (6.4-54.6) |
| No. younger than 18 y (%) | 13 (7) | 12 (6) |
| CML phase at time of transplantation, no. (%) | ||
| Chronic | 130 (67) | 142 (74) |
| Accelerated | 49 (25) | 38 (20) |
| Blast crisis | 12 (6) | 13 (7) |
| Juvenile | 2 (1) | 0 (0) |
| HLA allele match status, no. (%) | ||
| 10 of 10 matched | 91 (47) | 92 (48) |
| 9 of 10 matched | 46 (24) | 54 (28) |
| 8 or fewer of 10 matched | 56 (29) | 47 (24) |
| No. male patients (%) | 112 (58) | 110 (57) |
| GVHD prophylaxis, no. (%) | ||
| Calcineurin inhibitor + MTX* | 173 (90) | 168 (87) |
| Calcineurin inhibitor + MTX + other† | 20 (10) | 25 (13) |
For training data set and validation data set, n = 193 each.
MTX indicates methotrexate.
Tacrolimus was the calcineurin inhibitor for one patient from each of the training and validation data sets, respectively; the remaining patients received cyclosporine.
Other refers to a CD25-specific immunotoxin for 4 and 7 patients and to a humanized CD25-specific antibody for 16 and 18 patients from the training and validation data sets, respectively.